155 related articles for article (PubMed ID: 30362536)
21. Ether à go-go potassium channel expression in soft tissue sarcoma patients.
Mello de Queiroz F; Suarez-Kurtz G; Stühmer W; Pardo LA
Mol Cancer; 2006 Oct; 5():42. PubMed ID: 17022811
[TBL] [Abstract][Full Text] [Related]
22. Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21.
Mei L; Chen Y; Wang Z; Wang J; Wan J; Yu C; Liu X; Li W
Br J Pharmacol; 2015 May; 172(9):2232-45. PubMed ID: 25521075
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional and post-transcriptional mechanisms for oncogenic overexpression of ether à go-go K+ channel.
Lin H; Li Z; Chen C; Luo X; Xiao J; Dong D; Lu Y; Yang B; Wang Z
PLoS One; 2011; 6(5):e20362. PubMed ID: 21655246
[TBL] [Abstract][Full Text] [Related]
24. Comparative effects of liensinine and neferine on the human ether-a-go-go-related gene potassium channel and pharmacological activity analysis.
Dong ZX; Zhao X; Gu DF; Shi YQ; Zhang J; Hu XX; Hu MQ; Yang BF; Li BX
Cell Physiol Biochem; 2012; 29(3-4):431-42. PubMed ID: 22508050
[TBL] [Abstract][Full Text] [Related]
25. The plant alkaloid tetrandrine inhibits metastasis via autophagy-dependent Wnt/β-catenin and metastatic tumor antigen 1 signaling in human liver cancer cells.
Zhang Z; Liu T; Yu M; Li K; Li W
J Exp Clin Cancer Res; 2018 Jan; 37(1):7. PubMed ID: 29334999
[TBL] [Abstract][Full Text] [Related]
26. [Expression of Ether à go-go 1 and its molecular mechanism of regulating the malignant phenotype of osteosarcoma].
Chen ZD; Liu QJ; Zeng WR; Wu XY; Lin B; Wu J
Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):818-825. PubMed ID: 27998439
[No Abstract] [Full Text] [Related]
27. Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp.
Haraguchi Y; Ohtsuki A; Oka T; Shimizu T
BMC Pharmacol Toxicol; 2015 Dec; 16():39. PubMed ID: 26671227
[TBL] [Abstract][Full Text] [Related]
28. Eag1 potassium channels as markers of cervical dysplasia.
Ortiz CS; Montante-Montes D; Saqui-Salces M; Hinojosa LM; Gamboa-Dominguez A; Hernández-Gallegos E; Martínez-Benítez B; Del Rosario Solís-Pancoatl M; Garcia-Villa E; Ramírez A; Aguilar-Guadarrama R; Gariglio P; Pardo LA; Stühmer W; Camacho J
Oncol Rep; 2011 Dec; 26(6):1377-83. PubMed ID: 21887469
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of Eag1 potassium channels in clinical tumours.
Hemmerlein B; Weseloh RM; Mello de Queiroz F; Knötgen H; Sánchez A; Rubio ME; Martin S; Schliephacke T; Jenke M; Heinz-Joachim-Radzun ; Stühmer W; Pardo LA
Mol Cancer; 2006 Oct; 5():41. PubMed ID: 17022810
[TBL] [Abstract][Full Text] [Related]
30. Astemizole: an old anti-histamine as a new promising anti-cancer drug.
García-Quiroz J; Camacho J
Anticancer Agents Med Chem; 2011 Mar; 11(3):307-14. PubMed ID: 21443504
[TBL] [Abstract][Full Text] [Related]
31. Ether à go-go 1 silencing in combination with TRAIL overexpression has synergistic antitumor effects on osteosarcoma.
Wu J; Zeng T; Wu X; Gao Q; Zhai W; Ding Z
Cancer Biother Radiopharm; 2013 Feb; 28(1):65-70. PubMed ID: 23145797
[TBL] [Abstract][Full Text] [Related]
32. [Inhibitory effect of tetrandrine on angiogenesis].
Qian XP; Liu BR; Hu J; Li M; Hu WJ; Sun J; Yu LX
Ai Zheng; 2008 Oct; 27(10):1050-5. PubMed ID: 18851784
[TBL] [Abstract][Full Text] [Related]
33. Tetrandrine induces G1/S cell cycle arrest through the ROS/Akt pathway in EOMA cells and inhibits angiogenesis in vivo.
Xiao W; Jiang Y; Men Q; Yuan L; Huang Z; Liu T; Li W; Liu X
Int J Oncol; 2015 Jan; 46(1):360-8. PubMed ID: 25355542
[TBL] [Abstract][Full Text] [Related]
34. Eag1 K
Han B; Tokay T; Zhang G; Sun P; Hou S
Oxid Med Cell Longev; 2017; 2017():7371010. PubMed ID: 28367272
[No Abstract] [Full Text] [Related]
35. Potassium channel ether à go-go1 is aberrantly expressed in human liposarcoma and promotes tumorigenesis.
Wu J; Zhong D; Wei Y; Wu X; Kang L; Ding Z
Biomed Res Int; 2014; 2014():345678. PubMed ID: 25136578
[TBL] [Abstract][Full Text] [Related]
36. Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity.
Yunomae K; Ichisaki S; Matsuo J; Nagayama S; Fukuzaki K; Nagata R; Kito G
J Appl Toxicol; 2007; 27(1):78-85. PubMed ID: 17146843
[TBL] [Abstract][Full Text] [Related]
37. Effect of imipramine on ether à-go-go potassium channel (Kv1.10) expression in DU145 prostate cancer cells.
Söğüt F; Çömelekoğlu Ü; Dervişoğlu H; Eroğlu P; Yalin S; Yilmaz NŞ
Andrologia; 2022 Feb; 54(1):e14291. PubMed ID: 34729805
[TBL] [Abstract][Full Text] [Related]
38. EAG1 enhances hepatocellular carcinoma proliferation by modulating SKP2 and metastasis through pseudopod formation.
Chen J; Xuan Z; Song W; Han W; Chen H; Du Y; Xie H; Zhao Y; Zheng S; Song P
Oncogene; 2021 Jan; 40(1):163-176. PubMed ID: 33097858
[TBL] [Abstract][Full Text] [Related]
39. Long-term channel block is required to inhibit cellular transformation by human ether-à-go-go-related gene (hERG1) potassium channels.
Pier DM; Shehatou GS; Giblett S; Pullar CE; Trezise DJ; Pritchard CA; Challiss RA; Mitcheson JS
Mol Pharmacol; 2014 Aug; 86(2):211-21. PubMed ID: 24830940
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
